Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. - Test2 - elhamkhani - TriplyDB

Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.

Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.

http://www.wikidata.org/entity/Q33824463

about

Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations.Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models.Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.A Comparative Cytotoxic Evaluation of Disulfiram Encapsulated PLGA Nanoparticles on MCF-7 Cells.Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer.Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts.The comparative effects of diethyldithiocarbamate-copper complex with established proteasome inhibitors on expression levels of CYP1A2/3A4 and their master regulators, aryl hydrocarbon and pregnane X receptor in primary cultures of human hepatocytes Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death

P2860

Q26740191-F1E15394-1B17-44FF-B805-F82203C082AE Q35542866-F922BA43-01D4-44CC-B3A9-C845E0AE5C67 Q36820304-94A8912F-DD0C-4C61-8595-ED996B5D2AA0 Q37392908-596C06EC-AED5-4CF0-BE27-F8849AAA9CCD Q37696104-34535B65-C987-4362-8A03-A3237EE08ED9 Q41082509-3C1602E1-1327-45B3-9B82-BA373C57BC2D Q41553505-52AB429F-0BDE-4785-BF76-C334FDB75872 Q41887816-2E947622-0D8C-481A-A565-82D1666FB8AC Q46185130-01A4DDCA-A16C-4BFC-921B-E132BA92BEC4 Q49181990-6565FDE0-6672-4392-9CD6-011EE5108222 Q51642518-C809E238-12E6-4F74-9CE0-7F7F1A3E1EE6 Q58744474-F93C50A7-B8A9-4791-9AD3-2F81BAA1F52F

P2860

Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.

http://www.wikidata.org/entity/Q33824463

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@ast

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@en

type

label

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@ast

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@en

prefLabel

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@ast

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@en

P1433

Q33824463-8EE7CCCA-D14D-4379-945C-DF7EB420D927

P1476

Q33824463-7E663EFA-A981-4B24-8536-DACE8E7B8C48

P2093

Q33824463-1FFC127A-B8D2-4107-AA32-ED55C712B886

Q33824463-23264CAE-1F80-42EF-8A0E-674528D14C55

Q33824463-7C28047F-7B9E-47A4-91A9-21323CA690EE

Q33824463-7F972357-6541-4F05-AA74-60643686B9F4

Q33824463-804D4B71-12A3-4FE1-AC87-6629540AC50F

Q33824463-8CF0F005-2B4C-47EC-BC40-00F78D6E6A05

Q33824463-948FBC41-9FE2-4218-A5E8-8A91317072DF

Q33824463-A97AA08E-B729-47E8-8D39-0F2D688399E6

Q33824463-C734DF32-0514-4EB9-ACE3-0DC42E12EEA7

Q33824463-DA750F98-2139-438C-8243-7A5845A9CD9B

P2860

Q33824463-08A0510E-469D-4B21-958F-968476CDC1D5

Q33824463-1C22C109-FE8B-44B3-A13D-641CC7C57ADD

Q33824463-3EE9265F-5575-422C-8A16-4022EEC984E8

Q33824463-4C6F6DFD-0997-45C1-A791-B1BDE40473EF

Q33824463-4DABA9ED-9216-4610-BE4C-4321C1147A85

Q33824463-53772F73-8BE8-4737-8CC3-DCD067328323

Q33824463-60D3DEE0-6CFE-41B0-B348-FA683D9DA846

Q33824463-68DCDFB1-4CF2-4E6B-B6FA-4E82869981B5

Q33824463-73CDB900-3BF2-4329-AC8B-9DD07BAE936A

Q33824463-807E121C-F618-45CD-8BD4-12E7697E13C1

P2888

Q33824463-490C1596-CE19-4A39-8304-47F8A5A67871

P304

Q33824463-B6FB86C5-1876-4D65-8217-A10A344E4A22

P31

Q33824463-1BFAE964-D937-434A-988F-2065DA4844BD

P356

Q33824463-A1C964B3-6D5C-4A4B-B04B-317821B0FC55

P478

Q33824463-E3778D19-D067-463E-B099-C6FDB117AC55

P577

Q33824463-85B09112-E7CF-4E23-B029-68BFC00EEF21

P5875

Q33824463-0B4E998A-BCE6-45D7-BABD-E33D409C9185

P6179

Q33824463-E5A68A47-8C7C-4256-998B-C282B00A0E66

P698

Q33824463-0AC97858-5035-4D2F-B761-B49E7F6BF638

P932

Q33824463-205AE819-EAA3-4778-AED6-8B8D2DEC08F7

P356

1479-5876-12-163

P1433

Journal of Translational Medicine

P1476

Disulfiram targeting lymphoid ...... and NF-kB pathway inhibition.

@en

P2093

Bing Xu

http://www.w3.org/2001/XMLSchema#string

Feili Chen

http://www.w3.org/2001/XMLSchema#string

Huijuan Dong

http://www.w3.org/2001/XMLSchema#string

Jie Zha

http://www.w3.org/2001/XMLSchema#string

Peng Li

http://www.w3.org/2001/XMLSchema#string

Pengcheng Shi

http://www.w3.org/2001/XMLSchema#string

Rongwei Li

http://www.w3.org/2001/XMLSchema#string

Shiyun Wang

http://www.w3.org/2001/XMLSchema#string

Weiguang Wang

http://www.w3.org/2001/XMLSchema#string

Yanyan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Reactive oxygen special (ROS), troublemakers between nuclear factor-kB (NF-kB) and c-Jun NH2-terminal kinase (JNK)

The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?

Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

NRF2 and cancer: the good, the bad and the importance of context.

A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.

Reactive oxygen species mediate crosstalk between NF-kappaB and JNK.

HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway

Elevated copper and oxidative stress in cancer cells as a target for cancer treatment.

P2888

1479-5876-12-163

P304

163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-12-163

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263056537

http://www.w3.org/2001/XMLSchema#string

P6179

1040366412

http://www.w3.org/2001/XMLSchema#string

P698

24915933

http://www.w3.org/2001/XMLSchema#string

P932

4075939

http://www.w3.org/2001/XMLSchema#string